These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35697289)

  • 1. Angiotensin receptor/Neprilysin inhibitor effects in CRTd non-responders: From epigenetic to clinical beside.
    Sardu C; Massetti M; Scisciola L; Trotta MC; Santamaria M; Volpicelli M; Ducceschi V; Signoriello G; D'Onofrio N; Marfella L; Casolaro F; Amico MD'; Ruocco A; Balestrieri ML; Mauro C; Rafaniello C; Capuano A; Paolisso G; Marfella R
    Pharmacol Res; 2022 Aug; 182():106303. PubMed ID: 35697289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
    Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis.
    Wang Y; Zhou R; Lu C; Chen Q; Xu T; Li D
    J Am Heart Assoc; 2019 Jul; 8(13):e012272. PubMed ID: 31240976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of heart failure patients with reverse left ventricular remodelling post-angiotensin receptor blockers/neprilysin inhibitors therapy.
    Maizels L; Wasserstrum Y; Fishman B; Segev A; Ben-Nun D; Younis A; Freimark D; Mazin I; Grupper A
    ESC Heart Fail; 2022 Jun; 9(3):1682-1688. PubMed ID: 35178886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Experience of Angiotensin Receptor-Neprilysin Inhibition in Reduced Ejection Fraction Heart Failure Patients With Advanced Kidney Disease.
    Chang HY; Lin CC; Chao CJ; Lin YC; Wang YC; Liao CT; Huang JL; Lee YH; Huang CY; Chien LN; Hsu CY
    Mayo Clin Proc; 2023 Jan; 98(1):88-99. PubMed ID: 36109207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial Dysfunction Drives CRTd Outcome at 1-Year Follow-Up: A Novel Role as Biomarker for miR-130a-5p.
    Sardu C; Santulli G; Savarese G; Trotta MC; Sacra C; Santamaria M; Volpicelli M; Ruocco A; Mauro C; Signoriello G; Marfella L; D'Amico M; Marfella R; Paolisso G
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials.
    Bao J; Kan R; Chen J; Xuan H; Wang C; Li D; Xu T
    Pharmacol Res; 2021 Jul; 169():105573. PubMed ID: 33766629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reverse Cardiac Remodeling and ARNI Therapy.
    Abboud A; Januzzi JL
    Curr Heart Fail Rep; 2021 Apr; 18(2):71-83. PubMed ID: 33481182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ARNI in HFrEF-One-Centre Experience in the Era before the 2021 ESC HF Recommendations.
    Niemiec R; Morawska I; Stec M; Kuczmik W; Swinarew AS; Stanula A; Mizia-Stec K
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
    Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure.
    Sun Y; Song S; Zhang Y; Mo W; Zhang X; Wang N; Xia Y; Tse G; Liu Y
    ESC Heart Fail; 2022 Feb; 9(1):667-675. PubMed ID: 34779134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure.
    Fonarow GC; Hernandez AF; Solomon SD; Yancy CW
    JAMA Cardiol; 2016 Sep; 1(6):714-7. PubMed ID: 27437874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.
    Sardu C; Paolisso P; Sacra C; Santamaria M; de Lucia C; Ruocco A; Mauro C; Paolisso G; Rizzo MR; Barbieri M; Marfella R
    Cardiovasc Diabetol; 2018 Oct; 17(1):137. PubMed ID: 30348145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subjective and Objective Impact of Angiotensin Receptor-Neprilysin Inhibitors on Systemic Right Ventricle Patients.
    Ephrem G; McCollum JC; Green-Hess D; Guglin ME; Sawada SG; Rao RA
    Heart Lung Circ; 2022 Jul; 31(7):964-973. PubMed ID: 35279372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40.
    Zhao M; Xin Y; Li J; Cao X; Liu X
    Medicine (Baltimore); 2019 Sep; 98(39):e17296. PubMed ID: 31574852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
    von Lueder TG; Wang BH; Kompa AR; Huang L; Webb R; Jordaan P; Atar D; Krum H
    Circ Heart Fail; 2015 Jan; 8(1):71-8. PubMed ID: 25362207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac resynchronization therapy and its effects in patients with type 2 DIAbetes mellitus OPTimized in automatic vs. echo guided approach. Data from the DIA-OPTA investigators.
    Sardu C; Paolisso P; Ducceschi V; Santamaria M; Sacra C; Massetti M; Ruocco A; Marfella R
    Cardiovasc Diabetol; 2020 Nov; 19(1):202. PubMed ID: 33248462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction.
    Khariton Y; Fonarow GC; Arnold SV; Hellkamp A; Nassif ME; Sharma PP; Butler J; Thomas L; Duffy CI; DeVore AD; Albert NM; Patterson JH; Williams FB; McCague K; Spertus JA
    JACC Heart Fail; 2019 Nov; 7(11):933-941. PubMed ID: 31521679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of early initiation of sacubitril-valsartan therapy in patients with acute decompensated heart failure].
    Si JP; Chen YW; Yang J; Li X; Zhang YL; Liu JQ; Guo R; Wang K; Jiang YN; Xia YL; Liu Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Jun; 48(6):477-483. PubMed ID: 32842257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.